Sanofi Posts Strong Earnings as Dupixent Sales Keep Growing

Sanofi SA reported better-than-expected profit in the first quarter, boosted by strong demand for its blockbuster skin and asthma drug Dupixent.

Earnings per share, excluding some items, were €1.79 ($2.03), according to a statement Thursday. Analysts surveyed by Bloomberg had estimated €1.67.